arGEN-X (ARGX) Stock Price, Fundamentals & Analysis

What ARGX does

arGEN-X (ARGX) is a commercial-stage biotechnology company headquartered in Amsterdam, Netherlands, that develops therapies for autoimmune diseases. It operates in the Healthcare sector and is listed on the Euronext Brussels market, where it is part of the BEL 20 index. The company's approved treatments include VYVGART for generalized myasthenia gravis (gMG) and immune thrombocytopenia (ITP), and VYVGART HYTRULO for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). Its pipeline covers additional indications such as seronegative gMG, ocular myasthenia gravis, primary ITP, Graves' disease, myositis, Sjögren's disease, systemic sclerosis, and antibody-mediated rejection, along with candidates targeting neonatal Fc receptors, IL-6, immunoglobulin A, and Galectin-10.

Key numbers explained

• 845.2 EUR is the current share price, which reflects the market's latest valuation of one share on the Euronext Brussels exchange.
• A trailing P/E ratio of 36.6 means the stock trades at roughly 36.6 times the company's last twelve months of earnings per share (23.07 USD).
• The forward P/E ratio of 26.2 uses expected future earnings, often giving a sense of how the market prices in growth.
• 52.88 mld. EUR is the market capitalization, the total value of all outstanding shares, which places arGEN-X among large-cap Healthcare stocks.
• Revenue growth of 59.3% year over year shows how quickly the company's top line has expanded over the last twelve months (5.32 mld. USD).
• A profit margin of 32.3% and an operating margin of 32% indicate that roughly one third of revenue remains as profit after costs and operating expenses.
• The dividend yield is 0%, and 0% of earnings are paid out as dividends, meaning the company currently returns no cash to shareholders via dividends.
• A beta of -0.03 suggests the stock's price movement has a very weak negative correlation with the broader market.
• The 52-week price range of 568.4 – 925 shows the lowest and highest traded prices over the past year, with the current price 845.2 EUR closer to the high end.
• Return on equity of 23.6% measures how effectively the company generates profit from shareholders' equity.

What to watch

Investors often monitor pipeline updates and regulatory decisions, as new approvals or clinical results can shift expectations for a bioscience company like arGEN-X. Earnings reports, with the next one scheduled for 22 oct. 2026, provide a regular checkpoint for revenue, margin, and guidance trends. Broader factors such as healthcare policy, reimbursement decisions, and currency movements can also affect a stock traded on Euronext Brussels, especially one with significant international operations and revenue denominated in USD. Comparing arGEN-X with peers such as UCB (UCB) or Sonic Healthcare (SHL) can help frame its growth and valuation within the sector.